MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
To determine if treatment with AMG 706 (motesanib diphosphate) in combination with paclitaxel
and carboplatin improves overall survival compared to treatment with placebo in combination
with paclitaxel and carboplatin in subjects with advanced non-squamous NSCLC and in subjects
with adenocarcinoma histology (adenocarcinoma subpopulation).